Dr. Reddy’s Laboratories has informed that certain batches of semaglutide were found to be out of specification due to an issue associated with the active pharmaceutical ingredient (API) used in the product. The company is investigating the root cause and taking appropriate measures to ensure product quality. Until the issue is resolved, commercial supplies of the product will be delayed for a certain period of time. There is no impact on patient safety or on the product's existing global regulatory filings. The company remain committed to ensuring reliable global supplies of this important metabolic therapy. The management of the Company will host a conference call on Thursday, July 9, 2026 at 16:30 – 17:00 IST 07:00 – 07:30 ET to discuss the topic and answer any questions from the participants. The Pre-register link to join is enclosed. The transcript of the conference call will be available on the Company’s website: www.drreddys.com.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1950.00 |
| Dr. Reddys Labs. | 1226.50 |
| Cipla | 1433.80 |
| Lupin | 2504.10 |
| Zydus Lifesciences | 1152.45 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: